美股异动丨新药减重效果不及预期诺和诺德盘前暴跌近30% 礼来涨超12%

港股那点事12-20 19:24

诺和诺德(NVO.US)盘前一度暴跌近30%，其减肥药竞争对手礼来(LLY.US)盘前大涨超12%。诺和诺德周五表示，其实验性下一代减肥药CagriSema在后期试验中帮助超重患者减重22.7%，低于预期的25%。这一低于预期的数据对诺和诺德来说是一个打击，该公司原本希望CagriSema能成为比礼来的减肥药Zepbound更强大的产品，以接替其上一代减肥药Wegovy。投资者和分析师一直热切期待这些数据，以检验诺和诺德在激烈的抗肥胖市场竞争中是否拥有一个强大的后续产品来接替Wegovy。(格隆汇)

海量资讯、精准解读，尽在新浪财经APP

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2492941971?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-12-20 19:24","share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","id":"2492941971","market":"other","top_or_hot":-1,"title":"美股异动丨新药减重效果不及预期 诺和诺德盘前暴跌近30% 礼来涨超12%","media":"港股那点事","content":"<html><body><div>\n<p cms-style=\"font-L\"><a href=\"https://laohu8.com/S/NVO\">诺和诺德</a>(NVO.US)盘前一度暴跌近30%，其减肥药竞争对手<a href=\"https://laohu8.com/S/LLY\">礼来</a>(LLY.US)盘前大涨超12%。诺和诺德周五表示，其实验性下一代减肥药CagriSema在后期试验中帮助超重患者减重22.7%，低于预期的25%。这一低于预期的数据对诺和诺德来说是一个打击，该公司原本希望CagriSema能成为比礼来的减肥药Zepbound更强大的产品，以接替其上一代减肥药Wegovy。投资者和分析师一直热切期待这些数据，以检验诺和诺德在激烈的抗肥胖市场竞争中是否拥有一个强大的后续产品来接替Wegovy。(格隆汇)</p><div><img src=\"http://n.sinaimg.cn/spider20241220/536/w1308h828/20241220/a195-5e9813fa59e9b8d091b462171f762e71.png\"/><span></span></div><div><img src=\"http://n.sinaimg.cn/spider20241220/541/w1306h835/20241220/43da-d5790d3f41e71a89e403826dd69b5211.png\"/><span></span></div>\n<div></div>\n<div>\n<div><img src=\"\"/></div>\n<div>海量资讯、精准解读，尽在新浪财经APP</div>\n</div>\n</div></body></html>","source":"sina","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>美股异动丨新药减重效果不及预期 诺和诺德盘前暴跌近30% 礼来涨超12%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n美股异动丨新药减重效果不及预期 诺和诺德盘前暴跌近30% 礼来涨超12%\n</h2>\n\n<h4 class=\"meta\">\n\n<p class=\"head\">\n<strong class=\"h-name small\">港股那点事</strong><span class=\"h-time small\">2024-12-20 19:24</span>\n</p>\n\n</h4>\n\n</header>\n<article>\n<html><body><div>\n<p cms-style=\"font-L\"><a href=\"https://laohu8.com/S/NVO\">诺和诺德</a>(NVO.US)盘前一度暴跌近30%，其减肥药竞争对手<a href=\"https://laohu8.com/S/LLY\">礼来</a>(LLY.US)盘前大涨超12%。诺和诺德周五表示，其实验性下一代减肥药CagriSema在后期试验中帮助超重患者减重22.7%，低于预期的25%。这一低于预期的数据对诺和诺德来说是一个打击，该公司原本希望CagriSema能成为比礼来的减肥药Zepbound更强大的产品，以接替其上一代减肥药Wegovy。投资者和分析师一直热切期待这些数据，以检验诺和诺德在激烈的抗肥胖市场竞争中是否拥有一个强大的后续产品来接替Wegovy。(格隆汇)</p><div><img src=\"http://n.sinaimg.cn/spider20241220/536/w1308h828/20241220/a195-5e9813fa59e9b8d091b462171f762e71.png\"/><span></span></div><div><img src=\"http://n.sinaimg.cn/spider20241220/541/w1306h835/20241220/43da-d5790d3f41e71a89e403826dd69b5211.png\"/><span></span></div>\n<div></div>\n<div>\n<div><img src=\"\"/></div>\n<div>海量资讯、精准解读，尽在新浪财经APP</div>\n</div>\n</div></body></html>\n\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.sina.com.cn/stock/bxjj/2024-12-20/doc-ineachkr5809184.shtml\">港股那点事</a> </p>\n\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n</div>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999014898.SGD","symbol_name":"United Global Quality Growth Fund Dis SGD","start_time":0,"source_url":"https://finance.sina.com.cn/stock/bxjj/2024-12-20/doc-ineachkr5809184.shtml","article_id":"2492941971","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492941971","pubTimestamp":1734693840,"columns":[],"sourceInfo":{"source_id":"sina","name":"sina"},"weMediaInfo":null,"summary":"诺和诺德(NVO.US)盘前一度暴跌近30%，其减肥药竞争对手礼来(LLY.US)盘前大涨超12%。诺和诺德周五表示，其实验性下一代减肥药CagriSema在后期试验中帮助超重患者减重22.7%，低于预期的25%。这一低于预期的数据对诺和诺德来说是一个打击，该公司原本希望CagriSema能成为比礼来的减肥药Zepbound更强大的产品，以接替其上一代减肥药Wegovy。投资者和分析师一直热切期待这些数据，以检验诺和诺德在激烈的抗肥胖市场竞争中是否拥有一个强大的后续产品来接替Wegovy。(格隆汇)\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","collect":0,"end_time":0,"defaultTopTitle":"sina.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"SG9999014898.SGD":"United Global Quality Growth Fund Dis SGD","LU1814569148.SGD":"WELLINGTON GLOBAL QUALITY GROWTH \"D\" (SGDHDG) ACC","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","BK4588":"碎股","LLY":"礼来","SG9999018857.SGD":"United Global Quality Growth Fd Cl Acc SGD-H","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","LU0354030511.USD":"ALLSPRING  U.S. LARGE CAP GROWTH \"I\" (USD) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","SG9999014906.USD":"大华全球优质成长基金Acc USD","LU0354030438.USD":"富国美国大盘成长基金Cl A Acc","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4581":"高盛持仓","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU0109391861.USD":"富兰克林美国机遇基金A Acc","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU0385154629.USD":"贝莱德营养科学基金A2","LU1127390331.HKD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"A\" (HKD) ACC","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU1868837300.USD":"CT (LUX) I AMERICAN FUND \"9\" (USD) ACC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","BK4516":"特朗普概念","LU2237443465.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","LU1712237335.SGD":"Natixis Mirova Global Sustainable Equity H-R-NPF/A SGD","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","BK4532":"文艺复兴科技持仓","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","IE00BJLML261.HKD":"HSBC GLOBAL EQUITY INDEX \"HCH\" (HKD) ACC","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","LU1868837136.USD":"CT (LUX) I AMERICAN \"8\" (USD) ACC","BK4534":"瑞士信贷持仓","LU1868836591.USD":"CT (LUX) I AMERICAN \"1U\"(USD) ACC","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","BK4533":"AQR资本管理(全球第二大对冲基金)","LU1868836757.USD":"CT (LUX) I AMERICAN FUND \"2\" (USD) ACC","SG9999015978.USD":"利安颠覆性创新基金A","LU0122379950.USD":"贝莱德世界健康科学A2","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","NVO":"诺和诺德"},"translate_title":"Changes in U.S. stocks | The weight loss effect of new drugs is less than expected, Novo Nordisk plummeted nearly 30% before the market, Eli Lilly rose more than 12%","themeId":"a469344a0fb92d1bb998ed1b12947db3","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1,"LLY":1},"content_text":"诺和诺德(NVO.US)盘前一度暴跌近30%，其减肥药竞争对手礼来(LLY.US)盘前大涨超12%。诺和诺德周五表示，其实验性下一代减肥药CagriSema在后期试验中帮助超重患者减重22.7%，低于预期的25%。这一低于预期的数据对诺和诺德来说是一个打击，该公司原本希望CagriSema能成为比礼来的减肥药Zepbound更强大的产品，以接替其上一代减肥药Wegovy。投资者和分析师一直热切期待这些数据，以检验诺和诺德在激烈的抗肥胖市场竞争中是否拥有一个强大的后续产品来接替Wegovy。(格隆汇)\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"productRelease,movement","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492941971"}

美股异动丨新药减重效果不及预期 诺和诺德盘前暴跌近30% 礼来涨超12%

精彩评论

美股异动丨新药减重效果不及预期诺和诺德盘前暴跌近30% 礼来涨超12%